

INDEPENDENT AUDITOR'S REPORT

To: Directors and shareholders of Glenmark Pharmaceuticals B.V.
Gooimeer 1
1411 DC Naarden

We have audited the accompanying financial statements for the year ended March 31 2024 of Glenmark Pharmaceuticals B.V., Amsterdam, which comprise the balance sheet as at 31 March 2024, the profit and loss account for the year then ended and the notes, comprising a summary of the accounting policies and other explanatory information.

Management's responsibility

Management is responsible for the preparation and fair presentation of these financial statements and in accordance with Part 9 of Book 2 of the Dutch Civil Code. Furthermore management is responsible for such internal control as it determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Dutch law, including the Dutch Standards on Auditing. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.


In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion with respect to the financial statements

In our opinion, the financial statements give a true and fair view of the financial position of Glenmark Pharmaceuticals B.V. as at March 31, 2024 and of its result for the year then ended in accordance with Part 9 of Book 2 of the Dutch Civil Code.

Haarlem,



A.M. Lansbergen RA
Clic Accountants B.V.

Glenmark Pharmaceuticals B.V.

at Amsterdam

Financial report 2023/2024



Index

| | |
|---------------------------------------|----|
| Balance sheet as at March 31, 2024 | 3 |
| Profit and loss account for 2023/2024 | 5 |
| General notes | 6 |
| Accounting policies | 7 |
| Notes to balance sheet | 9 |
| Notes to profit and loss account | 13 |
| Other notes | 15 |

Balance sheet as at March 31, 2024

Assets

(after profit appropriation)

| | 31 March 2024 | | 31 March 2023 | |
|---------------------------|---------------|-------------------|---------------|-------------------|
| | € | € | € | € |
| <i>Non-current assets</i> | | | | |
| Intangible assets | | 59,295 | | 12,214 |
| Equipment | | 14,437 | | 11,340 |
| <i>Current assets</i> | | | | |
| Inventories | | 4,341,860 | | 3,441,586 |
| <i>Receivables</i> | | | | |
| Trade receivables | 5,842,896 | | 4,402,512 | |
| Group companies | 159,514 | | 35,009 | |
| Tax receivables | 125,312 | | 60,136 | |
| Other receivables | 54,161 | | 60,735 | |
| | | 6,181,883 | | 4,558,392 |
| Cash and cash equivalents | | 9,940,037 | | 5,809,740 |
| Total | | 20,537,512 | | 13,833,272 |

Equity and liabilities

(after profit appropriation)

| | 31 March 2024 | | 31 March 2023 | |
|---|---------------|-------------------|---------------|-------------------|
| | € | € | € | € |
| <i>Equity</i> | | | | |
| Share capital | 18,000 | | 18,000 | |
| Other reserves | 2,577,215 | | 2,231,598 | |
| | | 2,595,215 | | 2,249,598 |
| Non-current liabilities | | 40,210 | | - |
| <i>Current liabilities</i> | | | | |
| Trade payables | 254,224 | | 1,017,912 | |
| Group companies | 1,504,326 | | 695,083 | |
| Taxes payable and social security contributions payable | 89,921 | | 285,426 | |
| Accruals | 16,053,616 | | 9,585,253 | |
| | | 17,902,087 | | 11,583,674 |
| Total | | 20,537,512 | | 13,833,272 |

Profit and loss account for 2023/2024

| | 2023/2024 | | 2022/2023 | |
|---|-------------|-----------|-------------|-----------|
| | € | € | € | € |
| Net revenue | 11,471,969 | | 13,152,115 | |
| Other operating income | 219,768 | | 141,407 | |
| Cost of sales | -10,137,081 | | -11,442,375 | |
| Gross margin | | 1,554,656 | | 1,851,147 |
| Employee benefits | 860,156 | | 707,131 | |
| Amortisation, depreciation and impairment | 22,792 | | 17,113 | |
| <i>Other operating expenses</i> | | | | |
| Other operating expenses | 295,090 | | 718,388 | |
| Sum of expenses | | 1,178,038 | | 1,442,632 |
| Operating result | | 376,618 | | 408,515 |
| Financial income and expense | | 75,493 | | -5,134 |
| Result before tax | | 452,111 | | 403,381 |
| Income tax expense | | -106,494 | | -68,677 |
| Result after tax | | 345,617 | | 334,704 |

Glenmark Pharmaceuticals B.V., Amsterdam


General notes

Most important activities

The activities of Glenmark Pharmaceuticals B.V., having its legal seat at Amsterdam primarily consist of: the purchase and sales of medicine.

Location actual activities

The registered and actual address of Glenmark Pharmaceuticals B.V. is Gooimeer 1, 1411 DC te Naarden in Registered place of business and is registered at the chamber of commerce under number 50131893.



Accounting policies

General

General policies

The financial statements are drawn up in accordance with the provisions of Title 9, Book 2 of the Dutch Civil Code and the firm pronouncements in the Dutch Accounting Standards, as published by the Dutch Accounting Standards Board ('Raad voor de Jaarverslaggeving').

Accounting policies for the valuation of assets and equity and liabilities

Valuation of assets and liabilities and determination of the result takes place under the historical cost convention. Unless presented otherwise, the relevant principle for the specific balance sheet item, assets and liabilities are presented at face value.

Accounting policies for the income statement

Income and expenses are accounted for on accrual basis. Profit is only included when realized on balance sheet date. Losses originating before the end of the financial year are taken into account if they have become known before preparation of the financial statements.

Changes in accounting estimates

The commission on sales expenses have been deducted from the revenue. Due to the new classification, the comparable figures have also been adjusted.

Accounting policies for assets

Intangible assets

Intangible fixed assets are presented at cost less accumulated amortisation and, if applicable, less impairments in value.

Equipment

Tangible fixed assets are presented at cost less accumulated depreciation and, if applicable, less impairments in value.

Inventories

Inventories (stocks) are valued at historical price or production cost based on the FIFO method (first in, first out) or lower realisable value.

Receivables

Upon initial recognition the receivables are recorded at the fair value and subsequently valued at the amortized cost. The fair value and amortized cost equal the face value.

Cash and cash equivalents

Cash at banks and in hand represent cash in hand, bank balances and deposits with terms of less than twelve months. Overdrafts at banks are recognised as part of debts to lending institutions under current liabilities. Cash at banks and in hand is carried at nominal value.

Accounting policies for equity and liabilities

Non-current liabilities

Recorded interest-bearing loans and liabilities are valued at amortized cost.



Current liabilities

Kortlopende schulden worden bij de eerste verwerking gewaardeerd tegen reële waarde. Kortlopende schulden worden na eerste verwerking gewaardeerd tegen geamortiseerde kostprijs, zijnde het ontvangen bedrag rekening houdend met agio of disagio en onder aftrek van transactiekosten. Dit is meestal de nominale waarde.

Accounting policies for the income statement

Net revenue

Revenues from the goods supplied are recognised when all significant risks and rewards in respect of the goods have been transferred to the buyer.

Income tax expense

The corporation tax is calculated at the current rate on the result of the financial year, taking into account permanent differences between the profit calculation according to the annual accounts and the tax profit calculation, and where deferred tax assets (if applicable) are only valued insofar as the realization thereof probably is.

Notes to balance sheet

Intangible assets

| | 31 March 2024 | 31 March 2023 |
|---------------------|---------------|---------------|
| | € | € |
| Right of use assets | 59,295 | 12,214 |
| Total | <u>59,295</u> | <u>12,214</u> |

The overview below shows the movements in the intangible fixed assets during the financial year:

| | Right of use assets |
|--|------------------------|
| | € |
| <i>Carrying value April 1, 2023</i> | |
| Cost or manufacturing price | 36,643 |
| Accumulated amortisation and impairments | -24,429 |
| | <u>12,214</u> |
| <i>Movements 2023/2024</i> | |
| Additions | 63,472 |
| Disposals | -36,643 |
| Amortisation on disposals | 36,643 |
| Depreciation | -16,391 |
| | <u>47,081</u> |
| <i>Carrying value March 31, 2024</i> | |
| Cost or manufacturing price | 63,472 |
| Accumulated depreciation | -4,177 |
| | <u>59,295</u> |

Equipment

| | 31 March 2024 | 31 March 2023 |
|-----------------------|---------------|---------------|
| | € | € |
| Other tangible assets | 14,437 | 11,340 |
| Total | <u>14,437</u> | <u>11,340</u> |

The overview below shows the movements in the tangible fixed assets during the financial year:

| | Other tangible assets |
|--|-----------------------------|
| | € |
| <i>Carrying value April 1, 2023</i> | |
| Cost or manufacturing price | 25,481 |
| Accumulated amortisation and impairments | -14,141 |
| | <u>11,340</u> |
| <i>Movements 2023/2024</i> | |
| Additions | 9,498 |
| Depreciation | -6,401 |
| | <u>3,097</u> |
| <i>Carrying value March 31, 2024</i> | |
| Cost or manufacturing price | 34,978 |
| Accumulated amortisation and impairments | -20,541 |
| | <u>14,437</u> |
| Depreciation rate (average) | 20.0 |

Inventories

| | 31 March 2024 | 31 March 2023 |
|---------------------------------------|------------------|------------------|
| | € | € |
| Inventory of finished and trade goods | 4,341,860 | 3,441,586 |
| Total | <u>4,341,860</u> | <u>3,441,586</u> |

Receivables

| | 31 March 2024 | 31 March 2023 |
|--------------------------|------------------|------------------|
| | € | € |
| Trade receivables, gross | 5,842,896 | 4,402,512 |
| Group companies | 159,514 | 35,009 |
| <i>Tax receivables</i> | | |
| Corporate income tax | 125,312 | 60,136 |
| Other receivables | 54,161 | 60,735 |
| Total | <u>6,181,883</u> | <u>4,558,392</u> |

Cash and cash equivalents

| | <u>31 March 2024</u> | <u>31 March 2023</u> |
|--------------|----------------------|----------------------|
| | € | € |
| Bank credits | 9,940,037 | 5,809,740 |
| Total | <u>9,940,037</u> | <u>5,809,740</u> |

Equity

| | <u>31 March 2024</u> | <u>31 March 2023</u> |
|----------------|----------------------|----------------------|
| | € | € |
| Share capital | 18,000 | 18,000 |
| Other reserves | 2,577,215 | 2,231,598 |
| Total | <u>2,595,215</u> | <u>2,249,598</u> |

The overview below shows the movements in the equity during the financial year:

| | Share capital | Other reserves | Total |
|-------------------------------|------------------|-------------------|------------------|
| | € | € | € |
| Balance April 1, 2023 | 18,000 | 2,231,598 | 2,249,598 |
| <i>Movements 2023/2024</i> | | | |
| Result for the year | - | 345,617 | 345,617 |
| | <u>-</u> | <u>345,617</u> | <u>345,617</u> |
| Balance March 31, 2024 | <u>18,000</u> | <u>2,577,215</u> | <u>2,595,215</u> |

Share capital

The issued share capital of the company amounts to € 18.000, divided into € 18.000 ordinary shares. The total number of issued shares is 18.000.

Non-current liabilities

| | <u>31 March 2024</u> | <u>31 March 2023</u> |
|----------------|----------------------|----------------------|
| | € | € |
| Other payables | 40,210 | - |
| Total | <u>40,210</u> | <u>-</u> |

Disclosure

Repayment obligations falling due within 12 months from the end of the financial year, as set out above, are included in current liabilities.

Current liabilities

| | <u>31 March 2024</u> | <u>31 March 2023</u> |
|--|----------------------|----------------------|
| | € | € |
| Trade payables | 254,224 | 1,017,912 |
| Group companies | 1,504,326 | 695,083 |
| <i>Taxes payable and social security contributions payable</i> | | |
| VAT | 89,921 | 285,426 |
| Accruals | 16,053,616 | 9,585,253 |
| Total | <u>17,902,087</u> | <u>11,583,674</u> |

Notes to profit and loss account

Revenue and gross margin

| | 2023/2024 | 2022/2023 |
|--------------------------|-------------------|-------------------|
| | € | € |
| Net revenue | 11,471,969 | 13,152,115 |
| Other operating income | 219,768 | 141,407 |
| Operating income | 11,691,737 | 13,293,522 |
| Cost of sales | | |
| Purchase of traded goods | 11,009,627 | 12,555,077 |
| Change in inventory | -872,546 | -1,112,702 |
| | 10,137,081 | 11,442,375 |
| Gross margin | 1,554,656 | 1,851,147 |

Employee benefits

| | 2023/2024 | 2022/2023 |
|-------------------------------|----------------|----------------|
| | € | € |
| Wages and salaries | 690,993 | 606,551 |
| Social security contributions | 63,053 | 7,432 |
| Pension costs | 106,110 | 93,148 |
| Total | 860,156 | 707,131 |

Amortisation, depreciation and impairment

| | 2023/2024 | 2022/2023 |
|-------------------------------------|---------------|---------------|
| | € | € |
| Depreciation of right-to-use assets | 16,391 | 12,214 |
| Depreciation of tangible assets | 6,401 | 4,899 |
| Total | 22,792 | 17,113 |

Other operating expenses

| | <u>2023/2024</u> | <u>2022/2023</u> |
|---------------------------------------|------------------|------------------|
| | € | € |
| Other operating expenses | | |
| Advice | 104,428 | 89,073 |
| Transport expenses | 183,242 | 170,287 |
| Insurance expenses | 14,758 | 30,765 |
| Sales expenses | 31,949 | 42,514 |
| Subscriptions | 23,047 | 69,005 |
| Recruitment expenses | 20,263 | - |
| Office expenses | 23,786 | 12,858 |
| Audit, accounting and payrolling fees | 5,700 | 5,900 |
| Bank charges | 366 | 371 |
| Penalty | -150,714 | 280,000 |
| Other expenses | 38,265 | 17,615 |
| Total | <u>295,090</u> | <u>718,388</u> |

Financial income and expense

| | <u>2023/2024</u> | <u>2022/2023</u> |
|-------------------------------------|------------------|------------------|
| | € | € |
| Interest expenses other parties | 75,493 | -5,134 |
| Financial income and expense | <u>75,493</u> | <u>-5,134</u> |

Taxation

| | <u>2023/2024</u> | <u>2022/2023</u> |
|--|------------------|------------------|
| | € | € |
| Income tax expense from ordinary activities | <u>106,494</u> | <u>68,677</u> |

Other notes

Employees

The average number of employees during the year, converted to full-time equivalents, was as follows:

| <i>Average number of employees during the period</i> | 2023/2024 | 2022/2023 |
|--|-----------|-----------|
| | fte | fte |
| Active within the Netherlands | 6.0 | 5.0 |

Profit appropriation

Appropriation of the results

The annual report will be adopted in the general meeting of shareholders.

Proposed appropriation of the results

It is proposed that the appropriation of result by the board of directors and pursuant to the articles of association, an amount of € 345,617 will be added to the other reserves.

Signature

Amsterdam, 4 June 2024

Name

O. Bourne

Function

Managing director


Signature